What’s on the horizon? Biologics for nasal polyposis

Dupilumab in allergic fungal rhinosinusitis: A tertiary care center experience

Real-world analysis of dupilumab for nasal polyposis not meeting proposed biologic use guidelines

Increasing airflow to the nose: the effect of dupilumab in anosmia secondary to CRSwNP

Mepolizumab versus Dupilumab for Chronic Rhinosinusitis with Polyps

Sociodemographic Factors in Allergic Fungal Rhinosinusitis

Dupilumab Reduces Nasal Blockage and Improves Smell/Taste in Severe Chronic Rhinosinusitis with Nasal Polyps

Delay in Insurance Approval in Biologics in Asthma, and Chronic Rhinosinusitis may Increase Antibiotic Use and Healthcare Utilizations

Application of Artificial Intelligence and Deep Machine Learning in Rhinology: Current Status and Future Challenges

Why to Attend the American Rhinelogic Society

×
Advertisement